Cystinuria Market Insights, Epidemiology and Market Forecast-2028
1. Cystinuria incidence was about 1 in 7000 population in the United States.2. The men are affected about twice as often as women.3. Cystinuria prevalence in the US population is 1 in 10,000, that is there are approximately 33,000 affected individuals.
DelveInsight launched a new report on Cystinuria Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Cystinuria market report covers a descriptive overview and comprehensive insight of the Cystinuria epidemiology and Cystinuria market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Cystinuria market report provides insights on the current and emerging therapies.3. Cystinuria market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Cystinuria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cystinuria market.
Request for sample pages
“Cystinuria as a cause of 1–2% of stones observed in adults and about 10% of those occurring in children.”
Cystinuria is an inherited metabolic disorder characterized by the abnormal movement (transport) in the intestines and kidneys, of certain organic chemical compounds (amino acids). These include cystine, lysine, arginine, and ornithine. Excessive amounts of undissolved cysteine in the urine (cystinuria) cause the formation of stones (calculi) in the kidney, bladder, or ureter.The primary objective of cystinuria treatment is to reduce the cystine concentration in the urine. The foremost aim of cystinuria treatment is to prevent the formation of the stone. The first line of treatment is high-fluid intake, which prevents the formation of new stones and dissolves the previously formed ones. By increasing the volume of urine, the concentration of cystine in the urine is reduced which prevents cystine from precipitating from the urine and forming stones.Another strategy that has been attempted for cystinuria treatment is alkalization of the urine. The rationale is that in an alkaline (nonacidic) liquid, cystine tends to stay in solution and there it does no harm. Another approach for cystinuria treatment is the administration of D-penicillamine. D-penicillamine promotes the formation of cystine in a different chemical form (mixed disulfide), which is more soluble in the urine and is excreted easily.The global Cystinuria therapeutics market is further expected to increase by the major drivers such as rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2019–2028]. The dynamics of Cystinuria market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world. The launch of Cystinuria emerging therapies is expected during the forecast period of 2019–2028.
Companies covered1. Revive Therapeutics2. AdvicenneAnd many others
Drugs covered1. Bucillamine2. ADV7103And many others
Table of contents
1. Report Introduction2. Cystinuria Market Overview at a Glance3. Cystinuria Disease Background and Overview4. Cystinuria Epidemiology and Patient Population (7MM)5. Cystinuria Country- Wise Epidemiology5.1. United States5.2. EU5 Countries5.3. Germany5.4. France5.5. Italy5.6. Spain5.7. United Kingdom5.8. Japan6. Cystinuria Treatments & Medical Practices7. Cystinuria Emerging Therapies7.1. Key Cross Competition7.2. ADV7103: Advicenne7.3. Bucillamine: Revive Therapeutics8. Cystinuria Total 7MM Market Analysis9. Cystinuria 7MM Country-Wise Market Analysis10. United States Market Size11. EU5 Market Size11.1. Germany Market Size11.2. France Market Size11.3. Italy Market Size11.4. Spain Market Size11.5. United Kingdom Market Size12. Japan Market Size13. Market Drivers14. Market Barriers15. Cystinuria Report Methodology16. DelveInsight Capabilities17. Disclaimer18. About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/